Konstantinos Maitos

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

Deep Longevity Ltd. develops artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system and psychological levels. Its products include longevity cloud, recommendation engines, deep aging clocks and age metric reports. The company was founded in 2020 by Alex Zhavoronkov and is headquartered in San Diego, CA.

SIA Longenesis promotes collaboration between biomedical institutions, patient organizations, and research partners. The company is based in Riga, Latvia and has subsidiaries in Hong Kong. The Latvian company identifies biomedical data from metadata files, onboards population cohorts, and engages new patients in research. The company was founded by Garri Zmudze.

Colby is transitioning to a clinical stage drug development company. The company was launched as a Wisconsin Alumni Research Foundation (WARF) spin-out and is strategically aligned with leading clinicians and drug discovery scientists at the University of Wisconsin Paul P. Carbone Comprehensive Cancer Center (UWCCC). Colby is accessing data from funded grants and private investment to develop its therapeutic drugs for therapy-resistant and hypoxic conditions. Colby's lead drugs have unique mechanisms of action and target specific pathways. The company is focused on clinical development of its lead drugs, CPC-100 and -200, in patients with recurrent PCa and other solid tumors, respectively. In 2010, Colby plans to launch a Phase I/IIa study of CPC-100 in men with PCa who fail Androgen Depletion Therapy, as evidenced by rising PSA levels. CPC-200 is being scheduled for a Phase I/IIa in men with high-risk tumors. Colby's two pipeline drugs, CPC-300 and CPC-410 for therapy-resistant metastatic and hypoxic tumors are in late pre-clinical development and are funded by federal grants, including an awarded Colby SBIR grant and by private investors. The Company has demonstrated safety of its lead drugs following efficacy studies in rodents and toxicology studies in mice, rats, and dogs.

DECA Investments AIFM is a private equity firm based in Greece that focuses on investing in Greek SMEs with strong growth potential. DECA Investments AIFM is based in Maroussi, Greece, and has subsidiaries in Luxembourg and Greece. The Greek company prioritizes sustainability and observes environmental protection and social management policies before and throughout their investments. DECA Investments is the exclusive investment manager of Diorama Investments SICAR, S.A. and Diorama Investments II RAIF, S.C.A. The portfolio includes companies in the brewery, generic pharmaceuticals, and diversified branded sectors. The private company was founded by Alexander Katsouridis, and the CEO is Nickolaos J. Koulis.

Holmusk USA, Inc. develops predictive algorithms that offer insights for personalized care and population health management. It focuses on solving problems in healthcare for chronic diseases. The firm's products include AptCare Suite, which is a digital health management platform built for community chronic care, and MindLinc, which integrates mental and behavioural health and practice management at all levels. The company was founded by Nawal Roy in 2015 and is headquartered in Singapore.

Welltech Ventures is a venture capital firm founded in 2019 by Galit Horovitz and Amir Alroy. The firm is headquartered in Tel Aviv, Israel.

Starttech Ventures LLC (Starttech Ventures) is a venture capital firm founded in 2012 by Georgios Georgakopoulos, Katerina Kastriti, Dimitris Tsingos and Vangelis Mihalopoulos. The firm is headquartered in San Francisco, California.

Flipnode LLC is the company behind Yodeck, a digital signage platform that provides hardware and software for businesses to easily design, schedule, and display content on TV screens. The company is based in San Francisco, CA and was founded by Dimitris Tsingos and Vangelis Mihalopoulos. Yodeck offers solutions for various industries, including manufacturing, corporate communications, education, and retail. The platform allows businesses to engage with their employees, keep their teams informed, and advertise sales and promotions. Yodeck also provides free digital signage templates for businesses to create professional and attention-grabbing content. Vangelis Mihalopoulos has been the CEO since incorporation.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Human Longevity, Inc. provides precision health analytics to individuals through the Health Nucleus. The Health Nucleus is an assessment of current and future risk for cardiac, oncologic, metabolic and cognitive diseases and conditions. The firm offers database of sequenced genomes and phenotypic data. The company was founded by J. Craig Venter, Robert Joseph Hariri Gordon, and Peter H. Diamandis in 2013 and is headquartered in San Diego, CA.

Repair Biotechnologies, Inc. operates as a biotechnology company which develops clinic therapies. It specializes in developing reversing atherosclerosis and atrophy of the thymus. The company was founded by Reason Cherman and Bill Cherman in 2018 and is headquartered in Syracuse, NY.

Cellomics International Ltd. is a Chinese biotechnology company that focuses on developing and commercializing liquid biopsy products and services. The company is based in Hong Kong, Hong Kong. Cellomics International was founded by Christine Huang and Edwin Yu, with Christine Huang serving as the CEO since incorporation.

Bacmuno Biotechnology Ltd. provides bacteria-based immunotherapies against cancer. It applies Salmonella genetic modification technology to cancer immunotherapy in animals and humans. The company was founded on January 23, 2017 and is headquartered in Hong Kong.

Queen Mary Hospital operates general medical hospitals. The private company is based in Hong Kong, Hong Kong. The CEO of the Chinese company is Yau Fun Lau.

Nerviano Medical Sciences SRL provides pharmaceutical services. The company is headquartered in Nerviano, Italy.

Pretiosum Ventures Services Ltd (Pretiosum Ventures) is a venture capital firm founded in 2019 by Yana Abranova. The firm is headquartered in London, United kingdom.

Orisdx, Inc. provides a saliva-based molecular detection method to check oral cavity pre-malignancies and cancers. The private company is based in Chicago, IL. The company was founded by Evgeny G Izumchenko.

Y-Trap, Inc. develops novel immunotherapy for cancer. The private company is located in the US. The American company was founded by Evgeny G Izumchenko.

CellPly SRL develops and markets customized diagnostic tools for cancer treatment. The firm specializes in the design and marketing of solutions for defining the efficacy of immunotherapies and chemotherapies on cancer and immune cells. It offers a platform that analyzes ex-vivo samples and rare cells immediately after obtaining them from patients and preserving microenvironment conditions to readily provide information about tumor cell sensitivity to drugs and in-vivo status of single immune cells located close to tumor cells. The firm focuses on helping oncologists selecting the best treatment options, scientists studying cell response to therapy, and pharmaceutical companies increasing drug efficacy and rescuing drugs with limited efficacy through patient stratification. The company was founded by Massimo Bocchi and Roberto Guerrieri in 2013 and is headquartered in Bologna, Italy.

Sintetica SA operates as a pharmaceutical company that provides injectable anaesthetics and analgesics. The company was founded in 1921 and is headquartered in Mendrisio, Swizerland.

Novigenix SA develops molecular diagnostics for cancer. The firm specializes in new generation liquid biopsy tests for early detection of cancer and precision medicine. The company was founded by Sahar Hosseinian in 2014 and is headquartered in Epalinges, Switzerland.

Part of Motor Oil (Hellas) Corinth Refineries SA, Optima Bank SA is a brokerage services provider. The company is based in Athens, Greece. The Greek company was founded in 2000. Dimitrios Kyparissis has been the CEO of the company since 2019.

Seaport Global Securities LLC is a full service investment bank, capital markets advisory and research platform headquartered in New York City with offices across the US and in Europe. They are a subsidiary of Seaport Global Holdings LLC. The firm offers access to a broad selection of fixed income and equity products, as well as the market intelligence to provide insight to dynamic opportunities for its clients. Seaport Global Securities provides clients access to innovative trading solutions, competitive rates, quality execution, and superior service. Their equity trading team focuses on identifying liquidity in US, Canadian and European markets. The fixed income distribution platform covers all areas of the credit spectrum.